TY  - JOUR
AB  - BackgroundMelanoma represents one of the most aggressive skin cancers, responsible for over 75% of skin cancer-related deaths despite comprising only 5% of cases. Despite therapeutic advances, patient responses remain variable and unpredicv. The Signaling Lymphocytic Activation Molecule (SLAM) family regulates immune cell communication, with SLAMF8 being predominantly expressed on myeloid cells. However, SLAMF8's specific role in melanoma pathogenesis remains largely unexplored.MethodsIn this retrospective integrative study, we systematically investigated SLAMF8's role in melanoma through multi-omics analyses using TIMER, GEPIA, and UALCAN databases, following the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for observational data reporting. Functional studies were conducted in A-375 and SK-MEL-28 melanoma cell lines using siRNA-mediated knockdown, followed by migration, invasion, and proliferation assays. DNA methylation patterns were analyzed via the SMART database, while mutation profiles were examined using cBioPortal and COSMIC. Immune infiltration analysis was performed through TIMER, and pathway associations were investigated using Gene Set Enrichment Analysis and protein-protein interaction networks. Finally, two-sample Mendelian Randomization analysis assessed the causal relationship between SLAMF8 expression and melanoma susceptibility.ResultsSLAMF8 expression was significantly higher in metastatic melanoma compared to primary tumors, with expression patterns varying across disease stages and between sexes. Higher SLAMF8 expression correlated with improved disease-free and overall survival. Functional studies demonstrated that SLAMF8 knockdown significantly enhanced melanoma cell proliferation, migration, and invasion. DNA methylation analysis revealed significant negative correlations between methylation at specific CpG sites and SLAMF8 expression, with hypermethylation associated with worse survival outcomes. Mutation analysis identified alterations in 10.21% of melanoma patients. Immune infiltration studies demonstrated strong correlations between SLAMF8 expression and enhanced immune cell presence. GSEA linked SLAMF8 to critical immune pathways including allograft rejection, inflammatory response, and interferon signaling. Mendelian Randomization analysis established a protective causal relationship between SLAMF8 and melanoma risk (OR = 0.39, 95% CI = 0.21-0.74, p = 3.34e-03).ConclusionOur study demonstrates that SLAMF8 plays a critical role in melanoma by suppressing tumor progression and modulating the immune microenvironment. Elevated SLAMF8 expression in metastatic melanoma is associated with improved patient survival, suggesting its utility as a prognostic biomarker. Furthermore, its tumor-suppressive effects and immune-regulatory functions highlight SLAMF8 as a promising therapeutic target for melanoma treatment strategies.
AU  - Liu, J.*
AU  - Han, W.
AU  - Shen, G.*
C1  - 75921
C2  - 58409
CY  - 2455 Teller Rd, Thousand Oaks, Ca 91320 Usa
TI  - SLAMF8 expression and prognostic significance in melanoma: A multi-omics and Mendelian randomization study.
JO  - Cancer Biomark.
VL  - 42
IS  - 10
PB  - Sage Publications Inc
PY  - 2025
SN  - 1574-0153
ER  - 

TY  - JOUR
AB  - BACKGROUND: MicroRNAs constitute promising biomarkers. OBJECTIVE: The aim was to investigate diagnostic and prognostic implications of miR-182-5p and miR-205-5p in p16-positive and p16-negative oropharyngeal squamous cell carcinomas (OPSCCs). METHODS: Expression of miR-182-5p, miR-205-5p were determined via quantitative real-time-PCR in fresh frozen tissues of 26 p16-positive, 19 p16-negative OPSCCs and 18 HPV-negative oropharyngeal controls. Associations between miRNA-expression, clinicopathological characteristics and prognosis were analyzed. RESULTS: Higher miR-182-5p expression was associated with significant inferior disease-specific survival for p16-positive OPSCCs (HR = 1.98E+09, 95% CI 0-Inf; P= 0.028) and a similar trend was observed for p16-negative OPSCCs (HR = 1.56E+09, 95% CI 0-Inf; P= 0.051). Higher miR-205-5p expression was associated with an inferior progression-free survival (HR = 4.62, 95% CI 0.98-21.83; P= 0.034) and local control rate (HR = 2.18E+09, 95% CI 0-Inf; P= 0.048) for p16-positive OPSCCs. CONCLUSIONS: Results indicate that miR-182-5p and miR-205-5p can further stratify patients with p16-positive OPSCC into prognostic groups.
AU  - Weiss, B.G.*
AU  - Anczykowski, M.Z.*
AU  - Ihler, F.*
AU  - Bertlich, M.*
AU  - Spiegel, J.L.*
AU  - Haubner, F.*
AU  - Canis, M.*
AU  - Küffer, S.*
AU  - Hess J.
AU  - Unger, K.
AU  - Kitz, J.*
AU  - Jakob, M.*
C1  - 63035
C2  - 51223
SP  - 331-347
TI  - MicroRNA-182-5p and microRNA-205-5p as potential biomarkers for prognostic stratification of p16-positive oropharyngeal squamous cell carcinoma.
JO  - Cancer Biomark.
VL  - 33
IS  - 3
PY  - 2022
SN  - 1574-0153
ER  - 

TY  - JOUR
AB  - BACKGROUND: The pentaspan protein CD133 (Prominin-1) is a predictive marker and part of the signature of tumour-initiating cells (TICs) for various cancer entities. METHODS: The correlation of CD133 expression with clinical parameters was assessed in primary samples of head and neck squamous cell carcinomas (n = 98) and normal mucosas (n = 24). RESULTS: A gradual and inversely proportional correlation between CD133 expression in primary tumours and decreased overall survival was observed, along with a positive correlation with the presence of lymph node metastases. CONCLUSIONS: CD133 has the potential of being a novel clinically relevant prognostic marker for head and neck malignancies, which is possibly involved in regulation of tumourigenicity.
AU  - Canis, M.*
AU  - Lechner, A.*
AU  - Mack, B.*
AU  - Zengel, P.*
AU  - Laubender, R.P.*
AU  - Koehler, U.*
AU  - Heissmeyer, V.
AU  - Gires, O.
C1  - 23166
C2  - 31004
SP  - 97-105
TI  - CD133 is a predictor of poor survival in head and neck squamous cell carcinomas.
JO  - Cancer Biomark.
VL  - 12
IS  - 2
PB  - IOS Press
PY  - 2012
SN  - 1574-0153
ER  -